Suggested remit: To appraise the clinical and cost effectiveness of canagliflozin within its marketing authorisation for treating chronic kidney disease in people with type 2 diabetes. The Topic Selection Oversight Panel (TSOP) have determined that cangliflozin would be best assessed and included in the chronic kidney disease and Type 2 diabetes in adults: management update. Therefore the appraisal has been suspended from the Technology Appraisal work programme.
Suspended
- Status:
- Suspended
- Decision:
- Selected
- Process:
- TA
- ID number:
- 1653
Project Team
- Project lead
- Danielle Lees
Email enquiries
If you have any queries please email [email protected]
Stakeholders
- Companies sponsors
- Napp Pharmaceuticals (canagliflozin)
- Others
- Department of Health and Social Care
- NHS England
- NHS Newbury and District CCG
- NHS Sheffield CCG
- Welsh Government
- Patient carer groups
- BEMDA: Black and Ethnic Minority Diabetes Association
- Black Health Agency
- Diabetes Research and Wellness Foundation
- Diabetes UK
- Heart UK
- InDependent Diabetes Trust
- INPUT
- Kidney Care UK
- Kidney Research UK
- Muslim Council of Britain
- National Kidney Federation
- Network of Sikh Organisations
- Polycystic Kidney Disease Charity
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Stroke Association
- Professional groups
- 4front
- Association for the Study of Obesity
- Association of British Clinical Diabetologists
- Association of Renal Technologists
- British and Irish Hypertension Society
- British Association for Nursing in Cardiovascular Care
- British Association of Endocrine and Thyroid Nurses
- British Geriatrics Society
- British Heart Foundation
- British Renal Society
- National Metabolic Biochemistry Network
- Primary Care Diabetes Society
- Renal Association
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society for DGH Nephrologists
- Society for Endocrinology
- TREND UK
- UK Clinical Pharmacy Association
- UK Renal Pharmacy Group
- General commentators
- All Wales Therapeutic and Toxicology Centre
- Allied Health Professionals Federation
- Association of Renal Industries
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health, Social Services and Public Safety for Northern Ireland
- Diabetes UK Cymru
- Healthcare Improvement Scotland
- Medicines and Healthcare Products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Alliance
- NHS Confederation
- Scottish Medicines Consortium
- Welsh Endocrine and Diabetes Society
- Welsh Health Specialised Services Committee
- Welsh Kidney Patients Association
- Relevant research groups
- Cochrane Kidney and Transplant Group
- Cochrane Metabolic & Endocrine Disorders Group
- Genomics England
- MRC Clinical Trials Unit
- National Institute for Health Research
- The Society for Research in Rehabilitation
- Wellcome Trust
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 December 2020 | The Topic Selection Oversight Panel (TSOP) have determined that cangliflozin would be best assessed and included in the chronic kidney disease and Type 2 diabetes in adults: management update. Therefore the appraisal has been suspended from the Technology Appraisal work programme. |
| 22 December 2020 | Suspended. Suspended |
| 07 May 2020 | Invitation to participate |
| 07 May 2020 | Schedule affected by COVID-19. Invitation to participate issued but schedule affected by COVID-19 |
| 06 April 2020 | Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear. |
| 18 November 2019 - 16 December 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual